ClinicalTrials.gg
Sign In
CompletedNCT07347379Updated Oct 16, 2026

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

An observational study in Aphakia Cataract, sponsored by RxSight, Inc.. Completed at 6 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by RxSight, Inc. · Observational

Updated Oct 16, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Sex
All
01

Study summary

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

02

Conditions studied

  • Aphakia Cataract

Browse trials for

Keywords

  • Light Adjustable Lens LAL Intraocular lens
03

In context

Aphakia

69 studies on the registry are indexed under Aphakia; 6 are open to participants now.

This study's enrollment of 108 is above the median of 95 across 15 observational studies indexed under Aphakia.

Browse Aphakia studies →

Lead sponsor

RxSight, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include up to 335 subjects who were previously implanted with the LAL in the CSP-029 study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject and study eye with prior participation in the CSP-029 study and implanted with the LAL.

Exclusion criteria

Exclusion Criteria:

  • Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (actual)
Patient registry
No

Groups and cohorts

  • Light adjustable lens (LAL) and Light Delivery Device (LDD)

    Light adjustable lens (LAL) and Light Delivery Device (LDD)

    Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD)

Interventions

  • DeviceLight Adjustable lens (LAL) and Light Delivery Device (LDD)

    Experimental treatment group received Light adjustable lens with Light delivery Device treatments

06

What researchers measure

Primary outcomes

  1. Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit

    Time frame: Up to 55 months

  2. Mean manifest cylinder at the Long-Term follow up visit

    Time frame: Up to 55 months

07

Study locations

6 sites
  • Vance Thompson Vision
    Alexandria, Minnesota 56308, United States
  • Vance Thompson Vision
    Omaha, Nebraska 68137, United States
  • Key-Whitman Eye Center
    Dallas, Texas 75235, United States
  • Slade & Baker Vision
    Houston, Texas 77027, United States
  • Texas Eye Research Center
    Hurst, Texas 76054, United States
  • Focal Point Vision
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Aug 2026, 9 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2026 → Aug 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Jan 16, 2026
StartActual
Nov 13, 2025
Primary completionActual
Aug 17, 2026was Sep 2026
CompletionActual
Sep 9, 2026was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 16, 2026
Sites
5 sites added
Show 5 added (5 United States)
  • Vance Thompson Vision · Alexandria, United States
  • Vance Thompson Vision · Omaha, United States
  • Key-Whitman Eye Center · Dallas, United States
  • Slade & Baker Vision · Houston, United States
  • Texas Eye Research Center · Hurst, United States
Oct 16, 2026
Primary completion
Sep 2026→Aug 17, 2026 (actual)
Oct 16, 2026
Study completion
Dec 2026→Sep 9, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Enrolling by invitation→Completed
    5 sites added
    Show 5 added (5 United States)
    • Vance Thompson Vision · Alexandria, United States
    • Vance Thompson Vision · Omaha, United States
    • Key-Whitman Eye Center · Dallas, United States
    • Slade & Baker Vision · Houston, United States
    • Texas Eye Research Center · Hurst, United States
    Primary completion Sep 2026→Aug 17, 2026 (now actual)
    Study completion Dec 2026→Sep 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07347379
Lead sponsor
RxSight, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Nov 13, 2025
Primary completion
Aug 17, 2026
Completion
Sep 9, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Aphakia →

Other studies from this sponsor

RxSight, Inc.

Start the discussion